A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
Kathleen Medora / aacr - A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses PHILADELPHIA – A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who…
AI Summary: An experimental KRAS-targeting vaccine administered to people at high risk for pancreatic cancer proved safe and generated durable immune responses, suggesting a credible path toward interception of pancreatic ductal adenocarcinoma before it takes hold. Researchers report sustained antibody and/or T-cell activity, supporting further development and larger efficacy trials.
- Broader KRAS-targeting research and technological advances (3)
- Expert and community reactions to KRAS vaccine results (3)
- Phase I KRAS vaccine: safety and durable immune responses (3)
Broader KRAS-targeting research and technological advances
Expert and community reactions to KRAS vaccine results
Phase I KRAS vaccine: safety and durable immune responses
FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
abcnews - The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol
AI Summary: The FDA approved a first‑of‑its‑kind oral cholesterol medication intended to lower LDL in high‑risk patients, offering a cheaper, pill‑based alternative to costly PCSK9 injections. Regulators cleared the treatment after reviewing trial data showing substantial LDL reductions, positioning it as a potentially more accessible option for long‑term cardiovascular risk management.